Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2021
• Auteurs : Pierre JourdainBenoit BrillandOuassim MedhioubJeanne CaronClément SamoreauAssia DjemaRenaud GanseyJean-Philippe CoindreMaud CousinAnne Sophie GarnierNicolas HenrySamuel WacrenierJeremy RiouGiorgina Barbara PiccoliJf Augusto
• Organismes : Département de Néphrologie-Dialyse-Transplantation [CHU Angers] Innate Immunity and Immunotherapy Département de Néphrologie-Dialyse-Transplantation [CHU Angers] Micro et Nanomédecines Translationnelles Département de Néphrologie-Dialyse-Transplantation [CHU Angers] Département de Néphrologie-Dialyse-Transplantation [CHU Angers] Service de Néphrologie [CH Cholet] Service de néphrologie [CH Laval] Centre Hospitalier Le Mans (CH Le Mans) Département de Néphrologie-Dialyse-Transplantation [CHU Angers] Département de Néphrologie-Dialyse-Transplantation [CHU Angers] Département de Néphrologie-Dialyse-Transplantation [CHU Angers] Service de néphrologie [CH Laval] Département de Néphrologie-Dialyse-Transplantation [CHU Angers] Centre Hospitalier Le Mans (CH Le Mans) Innate Immunity and Immunotherapy Centre Hospitalier Universitaire d'Angers Service de néphrologie [CH Laval] Dipartimento di Scienze cliniche e biologiche [Torino, Italy] Innate Immunity and Immunotherapy Département de Néphrologie-Dialyse-Transplantation [CHU Angers]
• Publié dans Kidney International Reports le 26/10/2020

---

Résumé : No abstract available

---

Fichiers liés : 1-s2.0-S2468024920318714-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2021
• Auteurs : Yohan SantinSébastien LopezIsabelle AderSandrine AndrieuNicolas BlanchardAudrey CarrièreLouis CasteillaBéatrice CousinNoélie DavezacPhilipe Barreto de SoutoCedric DrayNicolas FazilleauDaniel Gonzalez-DuniaPierre GourdySophie Gillette-GuyonnetNabila Jabrane-FerratOksana KunduzovaFrank Lezoualc’hRoland S LiblauLaurent O MartinezCédric MoroPierre PayouxLuc PénicaudValérie Planat-BénardClaire RamponYves RollandJoost-Peter SchanstraFelipe SierraPhilippe P. ValetAudrey VarinNathalie VergnolleBruno VellasJosé ViñaBruno GuiardAngelo Parini
• Organismes : Institut des Maladies Métaboliques et Casdiovasculaires Centre de Recherches sur la Cognition Animale - UMR5169 Centre de Biologie Intégrative STROMALab Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps Institut du Vieillissement Centre de Physiopathologie Toulouse Purpan STROMALab STROMALab STROMALab Centre de Recherches sur la Cognition Animale - UMR5169 Centre de Biologie Intégrative Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps Institut du Vieillissement Institut des Maladies Métaboliques et Casdiovasculaires Centre de Physiopathologie Toulouse Purpan Centre de Physiopathologie Toulouse Purpan Institut des Maladies Métaboliques et Casdiovasculaires Institut du Vieillissement Gérontopôle Centre de Physiopathologie Toulouse Purpan Institut des Maladies Métaboliques et Casdiovasculaires Institut des Maladies Métaboliques et Casdiovasculaires Centre de Physiopathologie Toulouse Purpan Institut des Maladies Métaboliques et Casdiovasculaires Institut des Maladies Métaboliques et Casdiovasculaires Toulouse NeuroImaging Center STROMALab STROMALab Centre de Recherches sur la Cognition Animale - UMR5169 Centre de Biologie Intégrative Institut du Vieillissement Gérontopôle Institut des Maladies Métaboliques et Casdiovasculaires National Institute on Aging [Bethesda, USA] Institut des Maladies Métaboliques et Casdiovasculaires STROMALab Institut de Recherche en Santé Digestive Gérontopôle Epidémiologie et Analyses en Santé Publique : risques, maladies chroniques et handicap Universitat de València = University of Valencia = Universidade de Valencia Centre de Recherches sur la Cognition Animale - UMR5169 Centre de Biologie Intégrative Institut des Maladies Métaboliques et Casdiovasculaires
• Publié dans The Journal of Frailty & Aging le 24/10/2020

---

Résumé : Aging is the major risk factor for the development of chronic diseases. After decades of research focused on extending lifespan, current efforts seek primarily to promote healthy aging. Recent advances suggest that biological processes linked to aging are more reliable than chronological age to account for an individual's functional status, i.e. frail or robust. It is becoming increasingly apparent that biological aging may be detectable as a progressive loss of resilience much earlier than the appearance of clinical signs of frailty. In this context, the INSPIRE program was built to identify the mechanisms of accelerated aging and the early biological signs predicting frailty and pathological aging. To address this issue, we designed a cohort of outbred SWISS mice (1576 male and female mice) in which we will continuously monitor spontaneous and voluntary physical activity from 6 to 24 months of age under either normal or high fat/high sucrose diet. At different age points (6, 12, 18, 24 months), multiorgan functional phenotyping will be carried out to identify early signs of organ dysfunction and generate a large biological fluids/feces/organs biobank (100,000 samples). A comprehensive correlation between functional and biological phenotypes will be assessed to determine: 1) the early signs of biological aging and their relationship with chronological age; 2) the role of dietary and exercise interventions on accelerating or decelerating the rate of biological aging; and 3) novel targets for the promotion of healthy aging. All the functional and omics data, as well as the biobank generated in the framework of the INSPIRE cohort will be available to the aging scientific community. The present article describes the scientific background and the strategies employed for the design of the INSPIRE Mouse cohort.

---

Fichiers liés : INSPIRE Mouse cohort.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2021
• Auteurs : Benoît BatailleJade de SellePierre-Etienne MoussotPhilippe MartyStein SilvaPierre Cocquet
• Organismes : Centre Hospitalier de Narbonne Centre Hospitalier de Narbonne Centre Hospitalier de Narbonne Clinique Médipôle Garonne Toulouse NeuroImaging Center Pôle Anesthésie Réanimation [CHU de Toulouse] Centre Hospitalier de Narbonne
• Publié dans British Journal of Anaesthesia le 28/10/2020

---

Résumé : Background: Passive leg raising (PLR) predicts fluid responsiveness in critical illness, although restrictions in mobilising patients often preclude this haemodynamic challenge being used. We investigated whether machine learning applied on transthoracic echocardiography (TTE) data might be used as a tool for predicting fluid responsiveness in critically ill patients. Methods: We studied, 100 critically ill patients (mean age: 62 yr [standard deviation: 14]) with severe sepsis or septic shock prospectively over 24 months. Transthoracic echocardiography measurements were performed at baseline, after PLR, and before and after a standardised fluid challenge in learning and test populations (n=50 patients each). A 15% increase in stroke volume defined fluid responsiveness. The machine learning methods used were classification and regression tree (CART), partial least-squares regression (PLS), neural network (NNET), and linear discriminant analysis (LDA). Each method was applied offline to determine whether fluid responsiveness may be predicted from left and right cardiac ventricular physiological changes detected by cardiac ultrasound. Predictive values for fluid responsiveness were compared by receiver operating characteristics (area under the curve [AUC]; mean [95% confidence intervals]). Results: In the learning sample, the AUC values were PLR 0.76 (0.62-0.89), CART 0.83 (0.73-0.94), PLS 0.97 (0.93-1), NNET 0.93 (0.85-1), and LDA 0.90 (0.81-0.98). In the test sample, the AUC values were PLR 0.77 (0.64-0.91), CART 0.68 (0.54-0.81), PLS 0.83 (0.71-0.96), NNET 0.83 (0.71-0.94), and LDA 0.85 (0.74-0.96) respectively. The PLS model identified inferior vena cava collapsibility, velocity-time integral, S-wave, E/Ea ratio, and E-wave as key echocardiographic parameters. Conclusions: Machine learning generated several models for predicting fluid responsiveness that were comparable with the haemodynamic response to PLR.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2021
• Auteurs : Arthur BergerFederico RavaioliOana FarcauDavide FestiHoria StefanescuFrançois BuissonNathalie Ganne-CarrièAnnalisa BerzigottiSalvatore PettaSylvie Sacher HuvelinDominique VallaChristophe BureauAnne OlivierFrédéric ObertiJérôme BoursierJean Paul GalmicheJean Pierre VinelClotilde DuburqueAlain AttarIsabelle ArchambeaudR. BenamouzigMarianne GaudricDominique LuetPatrice CouzigouLucie PlancheEmmanuel CoronJean-Baptiste HiriartFaiza ChermakMaude CharbonnierPierre NahonPatrick MarcellinDominique GuyaderStanislas PolHélène FontaineDominique LarreyVictor de LedinghenDenis OuzanFabien ZoulimDominique RoulotAlbert TranJean-Pierre BronowickiJean-Pierre ZarskiVincent LeroyGhassan RiachiPaul CalèsJean-Marie PéronLaurent AlricMarc BourlièrePhilippe MathurinSebastien DharancyJean-Frédéric BlancArmand AbergelLawrence SerfatyAriane MallatJean-Didier GrangéPierre AttaliYannick BacqClaire WartelleThông DaoYves BenhamouChristophe PiletteChristine SilvainChristos ChristidisDominique CapronGérard ThiefinSophie HillaireVincent Di Martino
• Organismes : Centre Hospitalier Universitaire d'Angers Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques Alma Mater Studiorum Università di Bologna = University of Bologna Regional Institute of Gastroenterology and Hepatology [Cluj-Napoca] Alma Mater Studiorum Università di Bologna = University of Bologna Regional Institute of Gastroenterology and Hepatology [Cluj-Napoca] Centre Hospitalier Universitaire d'Angers Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques Hôpital Jean Verdier [AP-HP] Centre de Recherche des Cordeliers Université Paris 13 Hôpital Cochin [AP-HP] UFR Médecine [Santé] - Université Paris Cité
• Publié dans Clinical Gastroenterology and Hepatology le 30/10/2020

---

Résumé : Background & aims: Based on platelets and liver stiffness measurements, the Baveno VI criteria (B6C), the expanded B6C (EB6C), and the ANTICIPATE score can be used to rule out varices needing treatment (VNT) in patients with compensated chronic liver disease. We aimed to improve these tests by including data on the ratio of platelets to liver stiffness.Methods: In a retrospective analysis of data from 10 study populations, collected from 2004 through 2018, we randomly assigned data from 2368 patients with chronic liver disease of different etiologies to a derivation population (n = 1579; 15.1% with VNT, 50.2% with viral hepatitis, 28.9% with nonalcoholic fatty liver disease, 20.8% with alcohol-associated liver disease, with model for end-stage liver disease scores of 9.5 ± 3.0, and 93.0% with liver stiffness measurements ≥10 kPa) or a validation population (n = 789). Test results were compared with results from a sequential algorithm (VariScreen). VariScreen incorporated data on platelets or liver stiffness measurements and then the ratio of platelets to liver stiffness measurement, adjusted for etiology, patient sex, and international normalized ratio.Results: In the derivation population, endoscopies were spared for 23.9% of patients using the B6C (VNT missed in 2.9%), 24.3% of patients using the ANTICIPATE score (VNT missed in 4.6%), 34.5% of patients using VariScreen (VNT missed in 2.9%), and 41.9% of patients using the EB6C (VNT missed in 10.9%). Differences in spared endoscopy rates were significant (P ≤ .001), except for B6C vs ANTICIPATE and in missed VNT only for EB6C vs the others (P ≤ .009). VariScreen was the only safe test regardless of sex or etiology (missed VNT ≤5%). Moreover, VariScreen secured screening without missed VNT in patients with model for end-stage liver disease scores higher than 10. This overall strategy performed better than a selective strategy restricted to patients with compensated liver disease. Test performance and safety did not differ significantly among populations.Conclusions: In a retrospective study of data from 2368 patients with chronic liver disease, we found that the B6C are safe whereas the EB6C are unsafe, based on missed VNT. The VariScreen algorithm performed well in patients with chronic liver disease of any etiology or severity. It is the only test that safely rules out VNT and can be used in clinical practice.

---

Fichiers liés : S1542356520308338.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2021
• Auteurs : Cristoforo IncorvaiaMona Al‐ahmadIgnacio Javier Ansotegui-ZubeldiaStefania ArasiClaus BachertCatherine BosJean BousquetAndrzéj BozekD. CaimmiMoises CalderónT. Bruce CasaleAdnan CustovicFrédéric de BlayPascal DemolyPhilippe DevillierAlain DidierAlessandro Giovanni FiocchiAdam FoxPhilippe GevaertMaximiliano GomezEnrico HefflerNatalia IlinaCarla IraniMarek JutelEfstrathios KaragiannisLudger KlimekP. KunaRobin O'HehirOxana KurbachevaPaolo Maria MatricardiMário Morais‐almeidaRalph MösgesNatalija NovakYoshitaka OkamotoPetr PanznerNikolaos G. PapadopoulosHae‐sim ParkGiovanni PassalacquaRuby PawankarOliver PfaarPeter Schmid‐grendelmeierSilvia ScuratiMiguel Tortajada‐girbésCarmen VidalJ. Christian VirchowUlrich WahnMargitta WormPetra ZieglmayerGiorgio Canonica
• Organismes : ASST Pini-CTO Kuwait University Al-Rashed Allergy Center [Kuwait City] Hospital Quirónsalud Bizkaia [Bilbao] IRCCS Ospedale Pediatrico Bambino Gesù = Bambino Gesù Children’s Hospital Ghent University Hospital Karolinska Institutet [Stockholm] Karolinska University Hospital [Stockholm] Stallergenes SA CHU Montpellier = Montpellier University Hospital Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon Medical University of Silesia Hôpital Arnaud de Villeneuve [CHU Montpellier] Institut Desbrest d'Epidémiologie et de Santé Publique Imperial College London University of South Florida [Tampa] University of Manchester [Manchester] Centre Hospitalier Universitaire [Strasbourg] Institut Desbrest d'Epidémiologie et de Santé Publique Hôpital Arnaud de Villeneuve [CHU Montpellier] Epidemiology of Allergic and Respiratory Diseases Department [iPlesp] Hôpital Foch [Suresnes] Université Paris-Saclay Pôle Clinique des Voies respiratoires [CHU Toulouse] IRCCS Ospedale Pediatrico Bambino Gesù = Bambino Gesù Children’s Hospital Guy's and St Thomas' Hospitals Ghent University Hospital Humanitas Clinical and Research Center [Rozzano, Milan, Italy] Humanitas University [Milan] Federal Institute of Immunology of Russia [Moscou] Université Saint-Joseph de Beyrouth / Saint Joseph University of Beirut Wrocław Medical University Stallergenes SA Center for Rhinology and Allergology = Zentrum für Rhinologie und Allergologie Medical University of Łódź Monash University [Melbourne] Federal Medical-Biological Agency of Russia Charité - UniversitätsMedizin = Berlin University Medicine Hospital CUF Descobertas Universität zu Köln = University of Cologne Clinical Research International Ltd. University Hospital Bonn Chiba University Hospital Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic] University of Manchester [Manchester] National and Kapodistrian University of Athens Ajou University School of Medicine Università degli studi di Genova = University of Genoa = Université de Gênes Nippon Medical School [Tokyo, Japon] Philipps Universität Marburg = Philipps University of Marburg University hospital of Zurich [Zurich] Stallergenes SA Dr Peset University Hospital Universitat de València = University of Valencia = Universidade de Valencia Complejo Hospitalario Universitario de Santiago de Compostela [ESpaña] = USC University Hospital Complex [Spain] = Centre hospitalier universitaire de Saint-Jacques-de-Compostelle [Espagne] University of Rostock = Universität Rostock Charité - UniversitätsMedizin = Berlin University Medicine Charité - UniversitätsMedizin = Berlin University Medicine Humanitas Clinical and Research Center [Rozzano, Milan, Italy] Humanitas University [Milan]
• Publié dans Allergy le 26/10/2020

---

Résumé : The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single-allergen molecules and to distinguish the causative molecules from those merely cross-reactive, pursuit of patient's treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi-genomics, metabolomics, and breathomics, to forecast patient's responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes.

---

Fichiers liés : ALL-2020-00739.R2_Proof_hi.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2021
• Auteurs : Vincent FontaineLaëtitia Duboscq-BidotCharlène JouveMatthieu HamlinAngélique CurjolVéronique BriandPhilip JaniakJean-Sébastien HulotMarie-Pierre Pruniaux-HarnistPhilippe CharronEric Villard
• Organismes : Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Assistance publique - Hôpitaux de Paris (AP-HP)
• Publié dans Stem Cell Research le 01/11/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2021
• Auteurs : Christian JungHans FlaattenJesper FjølnerRaphael Romano BrunoBernhard WernlyAntonio ArtigasBernardo Bollen PintoJoerg SchefoldGeorg WolffMalte KelmMichael BeilSigal SviriPeter Vernon van HeerdenWojciech SzczeklikMiroslaw CzuczwarMuhammed ElhadiMichael JoannidisSandra OeyenTilemachos ZafeiridisBrian MarshFinn AndersenRui MorenoMaurizio CecconiSusannah LeaverAriane BoumendilDylan de LangeBertrand GuidetHans FlaattenBernhard WernlyAntonio ArtigasMichael BeilSigal SviriPeter Vernon van HeerdenWojciech SzczeklikMuhammed ElhadiTilemachos ZafeiridisRui MorenoMaurizio CecconiAriane BoumendilHazem Maarouf AbosheaishaaEnas AbualqumbozAbdullah Khudhur AhmedHazem AhmedZoi AidoniCesar AldecoaNica AlexandruYasmin Khairy Nasreldin Mohamed AliMohammed Al-SadawiKasper AndersenFinn AndersenRui AssisMohammed AzabAhmed AzzamMohamed Raafat BadawyIda Riise BallebyEberhard BarthEberhard BarthNawfel Ben-HamoudaGuillaume BeschSebastien BessetAnders Thais BjerregaardHelene BrixRaphael Romano BrunoJens BrushoejHelle BundgaardPhilippe BurtinAnais CaillardIsabel Canas-PerezCyril CharronEvangelia ChrisanthopoulouVittoria ComelliniAlex CornetPatricia Jimeno CuberoMiroslaw CzuczwarStéphane DaugerCristina Diaz-RodriguezWillem DieperinkZouhir DindaneMichel DjibréTom DormansAlexander DullenkopfGuillaume DumasYumna ElgazzarPhilipp EllerAhmed ElsakaMirjam EversAndreas FaltlhauserAida Fernández FerreiraJesper FjølnerYvan FleuryArnaud GalboisPierre GarconMarc GarnierRyszard GawdaAbdelilah GhannamUlrich GoebelGemma GomàBruno GoncalvesAndré GordinhoMartijn GroenendijkEmmanuel GuerotBertrand GuidetMohan GurjarHendrik HaakeLenneke HaasAyman Abdelmawgoad HabibMichael HahnMaria Aagaard HansenMomin Majed Yousuf HillesAliae HusseinDavid IglesiasMichael JoannidisChristian JungIgor JurcisinHans-Joachim KabitzMalte KelmDetlef Kindgen-MillesJakub KlimkiewiczKarl Friedrich KuhnAnselm KunsteinMuhammed KurtDylan de LangeSusannah LeaverMatthias LutzAta MahmoodpoorJulien MaizelNathalie MarinBrian MarshBuno MegarbaneDieter MesottenPatrick MeybohmChristian MeyerAngela Prado MiraSilvio Namendys-SilvaHelene Korvenius NedergaardSaad NseirSandra OeyenTheresa OlasveengenAna Isabel Pinho OliveiraJohanna OzielAntonios PapadogoulasDavid Perez-TorresBernardo Bollen PintoGaël PitonGaëtan PlantefeveTudor PoernerJesús PriegoAhmed RabhaWinfried RanderathJean-Herlé RaphaelenPascal ReperJean-Philippe RigaudSusana Arias RiveraAndrea RobertiLuis RomundstadNikoletta RovinaRehab SalahMahmoud SalehSusana SanchoMaria de Lurdes Campos SantosHenrique SantosStefan SchallerJoerg SchefoldMichael SchusterGonxhe ShalaBritt SjøbøStephan SteinerHans Frank StrietzelSigal SviriWalter SwinnenLuis Tamayo-LomasSamar TharwatTeresa TomasaStine UhrenholtMarie VaissiereArnaud ValentXavier ValetteThierry VanderlindenEric Mayor VázquezMercedes Ibarz VillamayorMaja VillefranceIngo VoigtKyrillos WassimMartin WelteGeorg WolffJakob WollbornBegoña Zalba-EtayoMarieke Zegers
• Organismes : Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière] Optimisation thérapeutique en Neuropsychopharmacologie
• Publié dans Critical Care le 31/10/2020

---

Résumé : Background The COVID-19 pandemic has led highly developed healthcare systems to the brink of collapse due to the large numbers of patients being admitted into hospitals. One of the potential prognostic indicators in patients with COVID-19 is frailty. The degree of frailty could be used to assist both the triage into intensive care, and decisions regarding treatment limitations. Our study sought to determine the interaction of frailty and age in elderly COVID-19 ICU patients. Methods A prospective multicentre study of COVID-19 patients ≥ 70 years admitted to intensive care in 138 ICUs from 28 countries was conducted. The primary endpoint was 30-day mortality. Frailty was assessed using the clinical frailty scale. Additionally, comorbidities, management strategies and treatment limitations were recorded. Results The study included 1346 patients (28% female) with a median age of 75 years (IQR 72–78, range 70–96), 16.3% were older than 80 years, and 21% of the patients were frail. The overall survival at 30 days was 59% (95% CI 56–62), with 66% (63–69) in fit, 53% (47–61) in vulnerable and 41% (35–47) in frail patients ( p < 0.001). In frail patients, there was no difference in 30-day survival between different age categories. Frailty was linked to an increased use of treatment limitations and less use of mechanical ventilation. In a model controlling for age, disease severity, sex, treatment limitations and comorbidities, frailty was independently associated with lower survival. Conclusion Frailty provides relevant prognostic information in elderly COVID-19 patients in addition to age and comorbidities. Trial registration Clinicaltrials.gov: NCT04321265 , registered 19 March 2020.

---

Fichiers liés : s13054-021-03551-3.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2021
• Auteurs : Myriam TaouqiMarianne VeyriSylvie BrégigeonMichèle PibarotCaroline SolasAlain MakinsonAnne-Geneviève MarcelinSylvain ChoquetJean-Philippe SpanoIsabelle Poizot-Martin
• Organismes : Assistance Publique - Hôpitaux de Marseille Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Hôpital Sainte-Marguerite [CHU - APHM] Aix Marseille Université Assistance Publique - Hôpitaux de Marseille Simulation and Modeling of Adaptive Response for Therapeutics in Cancer Aix Marseille Université Hôpital de la Timone [CHU - APHM] Université de Montpellier Centre Hospitalier Régional Universitaire [Montpellier] Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale Hôpital Sainte-Marguerite [CHU - APHM]
• Publié dans Bulletin du Cancer le 01/11/2020

---

Résumé : HIV testing is recommended at time of cancer diagnosis, HBV and HCV screening because of the risk of reactivation with certain anticancer drugs.This is a cross-sectional study. The objectives were to assess the screening practices in cancer patients and the satisfaction of professionals in the event of use of the CancerHIV network. A questionnaire drafted by the CancerHIV expert and the OncoPaca-Corse Regional Cancer Network (RCN) was distributed in the region at the end of 2018 (part 1: V1) before being extended to the national level via the CancerHIV network (part 2: V2). Participation reached 160 and 130 respondents (V1 and V2, respectively). At the initial cancer assessment, 23% of respondents declared that they systematically screened for HIV at V1 (V2: 17%), 25% for HBV (V2: 20%) and 24% for HCV (V2: 19%). Before immunotherapy, the rates were 54% for HIV in V1 (V2: 52%), 57% for HBV (V2: 60%) and 55% for HCV (V2: 57%). Among the respondents, satisfaction when requesting a regional or national remedy was high (almost 100%). Screening for HIV, HBV and HCV allows supervised prescription of immunosuppressive or cytotoxic treatment to a potentially immunosuppressed patient. This study, resulting of an original collaboration between a RCN and a national expert network, underlines the lack of screening at the 2 examined stages of patient care, and the need for raising practitioners' awareness to recommendations.

---

Fichiers liés : 1-s2.0-S000745512100045X-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2021
• Auteurs : Pauline Lasserre-ZuberMarianne ChavéeMarlène FaureSylvie RocheOlivier SoudièreJérôme MuttererJean-Philippe MaignelEmilien PoussetPatricia LemMartin LerembourePierre P. DevauxFrédérique SerreValerie CadotCyrille Saintenac
• Organismes : Génétique Diversité et Ecophysiologie des Céréales Génétique Diversité et Ecophysiologie des Céréales Groupe d'Etude et de contrôle des Variétés Et des Semences Unité Expérimentale PHénotypage Au Champ des Céréales (UE1375) Unité Expérimentale PHénotypage Au Champ des Céréales (UE1375) Institut de Biologie Moléculaire des Plantes Groupe d'Etude et de contrôle des Variétés Et des Semences BioGEVES BioGEVES Institut de Chimie de Clermont-Ferrand Florimond Desprez Unité Expérimentale PHénotypage Au Champ des Céréales (UE1375) Groupe d'Etude et de contrôle des Variétés Et des Semences Génétique Diversité et Ecophysiologie des Céréales
• Publié dans Innovations Agronomiques le 24/10/2020

---

Résumé : La contamination des grains par les mycotoxines et notamment le deoxynivalenol (DON) est un problème sanitaire majeur chez les céréales. Cette étude a permis de comparer un ensemble exhaustif de méthodologies pour évaluer le taux de grains symptomatiques suite à une attaque de Fusarium graminearum et la contamination des farines par le DON pour permettre une évaluation en routine de ces caractères dans les programmes de sélection. Grace à ces nouvelles méthodologies, le projet a également mis en avant sept régions du génome de blé impliquées dans la résistance aux DON ainsi que des marqueurs moléculaires utilisables en sélection pour construire des variétés plus résistantes, un enjeu prioritaire pour la filière céréalière

---

Fichiers liés : 2021_Lassere-Zuber_InnovAgro_Vol84.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/04/2021
• Auteurs : Alexis CourtyPierre MedrelTibault ReveyrandPhilippe BouysseJean-Michel NebusGeoffroy Soubercaze-Pun
• Organismes : Ampleon Systèmes RF XLIM Systèmes RF Systèmes RF Centre National d'Études Spatiales [Toulouse]
• Publié dans International Journal of Microwave and Wireless Technologies le 25/10/2020

---

Source